Priovant announces FDA approval of LISRAYA for dermatomyositis adults
Priovant says the FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis; it is now available in the U.S.
Story updates
07:29:03 PM UTC
SquawkNews
ROIV ROIVW - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.